New hope for Tough-to-Treat bile duct cancer?
NCT ID NCT07437287
Summary
This study is testing if adding a new drug called Mitazalimab to standard chemotherapy (mFOLFOX) works better than chemotherapy alone for people with advanced bile duct cancer that has progressed after initial treatment. About 160 participants will be randomly assigned to receive either the combination or just the chemo. The main goal is to see if the combination helps people live longer, and researchers will closely monitor safety and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHM - CHU La Timone
Marseille, France
-
APHP - Hopital Beaujon
Paris, France
-
CHU Brest
Brest, France
-
CHU Estaing
Clermont-Ferrand, France
-
CHU Grenoble Alpes
Grenoble, France
-
CHU Hotel Dieu
Nantes, France
-
CHU Lille
Lille, France
-
CHU Montpellier - Hôpital Saint Eloi
Montpellier, France
-
CHU Poitiers
Poitiers, France
-
CHU Tours
Tours, France
-
CHU de Bordeaux - Hopital Haut Leveque
Bordeaux, France
-
CHU de Dijon
Dijon, France
-
CHU de Lyon
Lyon, France
-
Centre Eugène Marquis
Rennes, France
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
Hopital du Confluent
Nantes, France
-
Institut Curie
Paris, France
-
Institut Jean Godinot
Reims, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
-
Institut de cancérologie de l'Ouest - Site Paul Papin
Angers, 49933, France
Conditions
Explore the condition pages connected to this study.